

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

DHHS

Stacie Weeks, JD MPH Administrator

DIVISION OF HEALTH CARE FINANCING AND POLICY

Helping people. It's who we are and what we do.

## **Silver State Scripts Board Meeting Minutes**

**Date of Meeting**: Thursday, October 05, 2023, at 4:00 PM

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and

Policy (DHCFP), Silver State Scripts Board.

Agend	Agenda Item Record				Notes	
1. Clo	sed Executive Session					
a.	Call to Order and Roll Call	Chairperson Mark Decerbo called the meeting to order at 4:00 p.m. on October 05, 2023.			<ul> <li>DHCFP Staff Present were as follows:</li> <li>Lither, Gabriel, Senior Deputy Attorney General (SDAG)</li> </ul>	
		Chairperson Decerbo took the roll.	Present	Absent	<ul> <li>Clemons, Roshanda, MD, Medicaid Medical Director</li> <li>Olsen, David, Social Services Chief III</li> </ul>	
		Mark Decerbo, Pharm.D., Chair	$\boxtimes$		Flowers, Ellen, Program Officer I	
		Kate Ward, Pharm.D., Vice-Chair	$\boxtimes$		,	
		Joseph Adashek, MD	$\boxtimes$		Magellan Rx Staff Present were as	
		Mark Crumby, Pharm. D.	$\boxtimes$		follows:	
		Elizabeth Gonzalez, Pharm.D.	$\boxtimes$		<ul> <li>Kim, James, Pharm.D., Dir.</li> </ul>	
		Sapandeep Khurana, MD	$\boxtimes$		Clinical Account Services	
		• Isabella Niezborala, Pharm.D.	$\boxtimes$		<ul> <li>Martinez, Chris, Sr.</li> </ul>	
		Leana Ramirez, Pharm.D.	$\boxtimes$		Business Analyst	
		Aditi Singh, MD		$\boxtimes$	<ul> <li>Melissa Perez, Sr. Business</li> <li>Analyst</li> </ul>	
b.	Financial Review of	Chairman Decerbo directed Dr. James Kim to proceed with the Financial Review of Drug classes with proposed changes up for review.				
	<b>Drug Classes with</b>					
	<b>Proposed Changes</b>					
		Dr. Kim reminded the board members that presented is confidential and should not be				

f the Established the products with	Drug			
ne products with	_			
ne products with	_			
	,			
meeting to ord				
meeting to ord		I I		
meeting to orde				
meeting to ora	Chairman Decerbo called the emergency meeting to order at 4:35			
p.m. on October 05, 2023.				
A quorum was present.  Chairman Decerbo took the roll.				
			Present	Absent
$\boxtimes$		Magellan Rx Staff Present were as follows:		
$\boxtimes$		Kim, James, Pharm.D., Dir.		
$\boxtimes$		Clinical Account Services		
$\boxtimes$		<ul> <li>Martinez, Chris, Sr.</li> </ul>		
$\boxtimes$		Business Analyst		
$\boxtimes$		<ul> <li>Melissa Perez, Sr. Business</li> </ul>		
$\boxtimes$		Analyst		
$\boxtimes$		The state of the s		
	$\boxtimes$	The public attendee list is included as Attachment A.		
		Note: Participants may not have chosen		
		to reveal their identity, and in the		
		absence of a sign-in sheet, the attendee list's accuracy is not assured		
Telephonic and web comment was called for, and the phone lines were opened.				

			No public comments were provided.	
c. Status Update by DHCFP		•	No announcements were provided.	
3. Clinical Presentations		l Presentations		
	A. For Possible Action: Discussion and possible adoption of Topical Analgesics.			
	i.	Public comment	Telephonic and web comment was called for, and the phone lines were opened.  No public comment was provided.	
	ii.	Drug class review presentation by MagellanRx	Dr. Kim proposed moving diclofenac 3% gel as preferred and moving Pennsaid to non preferred with a note that out of the topical diclofenac products, only 1% and Pennsaid and it's generic, the 2% is FDA approved for RTS but and diclofenac is not.  Dr. Kim recommended the Board consider the class clinically and therapeutically equivalent.	
	iii.	Board Member Comment	Dr. Joseph Adashek commented if there have been any head studies between Pennsaid and diclofenac.  Dr. Kim responded there has not been any head studies between the diclofenac products. They're just different strengths.1%, 2% and 3%.  Dr. Khurana comment if there's anything that is different or unique between the generic and brand.  Dr. Kim responded that the 2% both generic and the Pennsaid come in as a solution that comes out of a metered dose pump. But delivery mechanism wise, I think both are pretty much the same.	
iv. Discussion by Board Member Adashel Board and action therapeutically equivale		Board and action	Board Member Adashek moved to accept the class as clinically and therapeutically equivalent presented by Magellan, and Board Member Sapandeep Khurana seconded the motion.	

approve					
	therapeutic	A vote was taken, and the results were a			
equivale	•	attendance (in favor, against, and abster	itions where	e appli	cable):
agents i	n class.		Voc	No	Abst.
		Mark Decerbo, Pharm.D., Chair	Yes ⊠	No	
		<ul> <li>Mark Decerbo, Pharm.D., Chair</li> <li>Kate Ward, Pharm.D., Vice-Chair</li> </ul>			
		·			
		Joseph Adashek, MD     Marth Cruseley, Bharras B	$\boxtimes$		
		Mark Crumby, Pharm.D			
		Elizabeth Gonzalez, Pharm.D.			
		Sapandeep Khurana, MD			
		Isabella Niezborala, Pharm.D	$\boxtimes$		
		Leana Ramirez, Pharm.D			
		Aditi Singh, MD			$\boxtimes$
v. Presentat		Dr. Kim recommended moving brand Pe		•	
	endations	adding the generic diclofenac 3% gel on	the PDL as p	oreferr	ed.
	nclusion by				
Magellan		Decod week as Whomes a second to see as			l
	on by Board	Board member Khurana moved to appro			_
for appro	on by Board	presented by Magellan with a friendly re			-
• • • • • • • • • • • • • • • • • • • •	inclusion	Rx and DHCFP can possibly notify member and Vice Chair Kate Ward seconded the		r or the	change
on the PE		and vice chair Rate Ward Seconded the	motion.		
On the re	JL.	A vote was taken, and the results were a	s follows fro	m mer	mbers in
		attendance (in favor, against, and abster	ntions where	e appli	cable):
			Yes	No	Abst.
		Mark Decerbo, Pharm.D., Chair	$\boxtimes$		
		Kate Ward, Pharm.D., Vice-Chair	$\boxtimes$		
		<ul> <li>Joseph Adashek, MD</li> </ul>	$\boxtimes$		
		Mark Crumby, Pharm.D	$\boxtimes$		
		<ul> <li>Elizabeth Gonzalez, Pharm.D.</li> </ul>	$\boxtimes$		
		Sapandeep Khurana, MD	$\boxtimes$		

	■ Isabella Niezborala, Pharm.D      □ □ □	
	• Leana Ramirez, Pharm.D	
	■ Aditi Singh, MD	
vii. Board Member Comment	Dr. Adashek commented regarding how recipients will be notified of the change.	
	Dr. Khurana commented if there is going to be a substitution that the pharmacy can do.	
B. Closing Discussion		
<ul><li>i. Public comments on any subject</li></ul>	No public comments were provided.	
ii. Date and location	Date: December 14, 2023.	
of the next meeting.	Location: TBD	
iii. Status Update by DHCFP	Chief of Pharmacy Services, David Olsen, provided announcements.	
	We appreciate the board's time, especially today, to take up this item	
	and have an extra meeting. I would also like to let the board know it	
	has been a pleasure working with the DHCFP and this board in	
	particular. I will be taking another position on October 23rd. My last	
	day with this with DHCFP is October 19th, which will be the day of our	
	next DUR board meeting.	
iv. Adjournment	Chairman Decerbo adjourned the meeting at 5:05 PM.	

## Attachment A – Members of the Public in Attendance

Mark Rosenberg Brooke Gruger Rogie Arellano

Dana Vaughns /US Jeana Colabianchi

## **Attachment B – Submitted Written Comment**

None